Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $30.0 million.

  • Krystal Biotech's Shares Outstanding (Diluted Average) rose 70.95% to $30.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $30.0 million, marking a year-over-year increase of 70.95%. This contributed to the annual value of $30.0 million for FY2025, which is 70.95% up from last year.
  • According to the latest figures from Q4 2025, Krystal Biotech's Shares Outstanding (Diluted Average) is $30.0 million, which was up 70.95% from $29.8 million recorded in Q3 2025.
  • Krystal Biotech's Shares Outstanding (Diluted Average)'s 5-year high stood at $30.0 million during Q4 2025, with a 5-year trough of $21.3 million in Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $26.8 million, with a median of $27.2 million in 2023.
  • Per our database at Business Quant, Krystal Biotech's Shares Outstanding (Diluted Average) skyrocketed by 1816.62% in 2022 and then decreased by 23.08% in 2025.
  • Quarter analysis of 5 years shows Krystal Biotech's Shares Outstanding (Diluted Average) stood at $22.2 million in 2021, then rose by 14.85% to $25.5 million in 2022, then grew by 8.87% to $27.8 million in 2023, then grew by 7.16% to $29.7 million in 2024, then increased by 0.71% to $30.0 million in 2025.
  • Its last three reported values are $30.0 million in Q4 2025, $29.8 million for Q3 2025, and $29.8 million during Q2 2025.